Format

Send to

Choose Destination
Neurologist. 2019 Sep;24(5):152-154. doi: 10.1097/NRL.0000000000000243.

Glial Fibrillary Acidic Protein (GFAP) Autoimmunity in the Setting of Seropositive Rheumatoid Arthritis Treated With Etanercept.

Author information

1
Department of Neurology.
2
Division of Rheumatology, Mayo Clinic, Rochester, MN.
3
Department of Pathology, Mayo Clinic, Jacksonville, FL.

Abstract

INTRODUCTION:

Glial fibrillary acidic protein (GFAP) immunoglobulin G is a recently discovered biomarker of an autoimmune central nervous system disorder characterized by a steroid-responsive meningoencephalomyelitis.

CASE REPORT:

A 63-year-old man with rheumatoid arthritis on etanercept presented with steroid-responsive subacute encephalopathy and foot drop. Brain and sural nerve biopsies demonstrated a T-cell perivascular infiltrate. Cerebrospinal fluid studies 18 months into the course of the illness demonstrated a GFAP antibody on mouse tissue immunofluorescence confirmed by cell-based assay. The patient was treated with steroids and cyclophosphamide leading to resolution of his symptoms.

CONCLUSION:

This case expands on the previously reported cases of GFAP immunoglobulin G autoimmunity by describing an associated inflammatory large fiber peripheral neuropathy.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center